Hempsana Holdings Ltd. has completed its largest commercial scale run of cannabigerol (CBG) at its manufacturing facility in Goderich, Ontario, Canada.
The product from this first run was primarily used for customer samples and to provide material as a part of a tolling agreement. Since this initial production run, Hempsana has increased its production by more than 1,000% and will continue to dedicate a significant portion of its production capacity to CBG, as well as other minor cannabinoids.
Hempsana has received inquiries for CBG, which is a rare cannabinoid with distinctive properties.
“During the third quarter, our product development team focused on scaling and optimizing our minor cannabinoid production processes,” said Randy Ko, president and CEO of Hempsana. “With initial orders for CBG targeted for early December delivery, we are excited for the Canadian consumers as they can look forward to the launch of new unique curated cannabis products fortified with Hempsana’s high-quality CBG cannabinoid extracts by many of the familiar cannabis brands in the market.”